EUVIMEDEUVIMED entdecken
Pragmatische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan‐Canadian, randomized control trial

Hannah Crepeault, Lianping Ti, Paxton Bach iD, Evan Wood, Didier Jutras-Aswad iD, Bernard Le Foll, Ron Lim, Maria E Socias iD

The American Journal on Addictions · 2025

DOI: 10.1111/ajad.13635 ↗

Kurz gefasst

Pragmatische Studie in der Zeitschrift The American Journal on Addictions, 2025. Verfasst von Hannah Crepeault und 7 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Methadone, Opiate Substitution Treatment, Opioid-Related Disorders. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Michael Smith Health Research BC (MSHRBC)/St. Paul's Foundation Scholar Award, Cordula and Gunter Paetzold Fellowship and the Canadian Graduate Scholarships Master's Program through the University of British Columbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives History of nonfatal overdose (NFO) is common among people who use opioids, but little is known about opioid agonist treatment (OAT) outcomes for this high‐risk subpopulation. The objective of this study was to investigate the relative effectiveness of buprenorphine/naloxone and methadone on retention and suppression of opioid use among individuals with opioid use disorder (OUD) and history of NFO.

Methods

Secondary analysis of a pan‐Canadian pragmatic trial comparing flexible take‐home buprenorphine/naloxone and supervised methadone for people with OUD and history of NFO. Logistic regression was used to examine the impact of OAT on retention in the assigned or in any OAT at 24 weeks and analysis of covariance was used to examine the mean difference in opioid use between treatment arms.

Results

Of the 272 randomized participants, 155 (57%) reported at least one NFO at baseline. Retention rates in the assigned treatment were 17.7% in the buprenorphine/naloxone group and 18.4% in the methadone group (adjusted odds ratio [AOR] = 0.54, 95% CI: 0.17–1.54). Rates of retention in any OAT were 28% and 20% in the buprenorphine/naloxone and methadone arms, respectively (AOR = 1.55, 95% CI: 0.65–3.78). There was an 11.9% adjusted mean difference in opioid‐free urine drug tests, favoring the buprenorphine/naloxone arm (95% CI: 3.5–20.3; p = .0057). Conclusions and Scientific Significance Among adults with OUD and a history of overdose, overall retention rates were low but improved when retention in any treatment was considered. These findings highlight the importance of flexibility and patient‐centered care to improve retention and other treatment outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethadoneOpiate Substitution TreatmentOpioid-Related DisordersAdultFemaleHumansMaleMiddle AgedAnalgesics, OpioidBuprenorphineBuprenorphine, Naloxone Drug CombinationCanadaDrug OverdoseNaloxoneNarcotic AntagonistsTreatment Outcome

Substanzen

Analgesics, OpioidBuprenorphineBuprenorphine, Naloxone Drug CombinationMethadoneNaloxoneNarcotic Antagonists

Autor:innen und Institutionen

  • British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
  • Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada.
  • Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada.
  • Department of Pharmacology and Toxicology, Faculty of Medicine, Medical Sciences Building, University of Toronto, Toronto, Ontario, Canada.
  • Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Paxton Bach, Didier Jutras-Aswad, Maria E Socias

Förderung

  • CIHR
  • Michael Smith Health Research BC (MSHRBC)/St. Paul's Foundation Scholar Award
  • Cordula and Gunter Paetzold Fellowship and the Canadian Graduate Scholarships Master's Program through the University of British Columbia
  • Fonds de Recherche du Québec en Santé
  • CAMH
  • Canadian Research Initiative in Substance Misuse
  • MSHRBC Scholar Award
  • Canada Research Chair by CIHR

Zitieren

APA

Crepeault, H., Ti, L., Bach, P., Wood, E., Jutras-Aswad, D., Le Foll, B., Lim, R., & Socias, M. E. (2025). Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan‐Canadian, randomized control trial. The American Journal on Addictions. https://doi.org/10.1111/ajad.13635

Vancouver

Crepeault H, Ti L, Bach P, Wood E, Jutras-Aswad D, Le Foll B, et al. Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan‐Canadian, randomized control trial. The American Journal on Addictions. 2025. doi:10.1111/ajad.13635

BibTeX
@article{Crepeault2025,
  author = {Crepeault, Hannah and Ti, Lianping and Bach, Paxton and Wood, Evan and Jutras-Aswad, Didier and Le Foll, Bernard and Lim, Ron and Socias, Maria E},
  title = {Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan‐Canadian, randomized control trial},
  journal = {The American Journal on Addictions},
  year = {2025},
  doi = {10.1111/ajad.13635}
}
Kostenlos starten →